Synonyms: L/105 | Rifamycin L 105 | Xifaxan®
rifaximin is an approved drug (FDA (2004))
Compound class:
Synthetic organic
Comment: Rifaximin is a semisynthetic derivative of rifamycin and belongs to the ansamycin group of antibacterial compounds [1]. It has broad spectrum activity against Gram-positive and Gram-negative bacteria.
|
|
Classification ![]() |
|
Compound class | Synthetic organic |
Approved drug? | Yes. FDA (2004) |
International Nonproprietary Names ![]() |
|
INN number | INN |
5244 | rifaximin |
Synonyms ![]() |
L/105 | Rifamycin L 105 | Xifaxan® |
Database Links ![]() |
|
Specialist databases | |
Antibiotic DB
![]() |
Rifaximin |
Other databases | |
CAS Registry No. | 80621-81-4 (source: Scifinder) |
ChEBI | CHEBI:75246 |
ChEMBL Ligand | CHEMBL1617 |
DrugBank Ligand | DB01220 |
GtoPdb PubChem SID | 464244153 |
PubChem CID | 6436173 |
RCSB PDB Ligand | RXM |
Search Google for chemical match using the InChIKey | NZCRJKRKKOLAOJ-XRCRFVBUSA-N |
Search Google for chemicals with the same backbone | NZCRJKRKKOLAOJ |
Search PubMed clinical trials | rifaximin |
Search PubMed titles | rifaximin |
Search PubMed titles/abstracts | rifaximin |
UniChem Compound Search for chemical match using the InChIKey | NZCRJKRKKOLAOJ-XRCRFVBUSA-N |
UniChem Connectivity Search for chemical match using the InChIKey | NZCRJKRKKOLAOJ-XRCRFVBUSA-N |
Wikipedia | Rifaximin |
Product supplier links are provided as a service to assist in identifying commercial suppliers of reagents that are mentioned on the IUPHAR/BPS Guide to PHARMACOLOGY database website, and do not imply their endorsement by NC-IUPHAR.
Links are provided in return for sponsorship, used to fund improvements to this database. The sponsorship account is managed and audited by the University of Edinburgh, a charitable body registered in Scotland, SC005336. If you are interested in sponsoring the database, please contact us.
✖